A Case of Severe Hepatic Dysfunction Initially Diagnosed as an Immune-related Adverse Event (irAE) Due to Pembrolizumab Treatment for Pulmonary Squamous Cell Carcinoma, Later Identified as Distal Cholangiocarcinoma Following Surgery
A Case of Severe Hepatic Dysfunction Initially Diagnosed as an Immune-related Adverse Event (irAE) Due to Pembrolizumab Treatment for Pulmonary Squamous Cell Carcinoma, Later Identified as Distal Cholangiocarcinoma Following Surgery
Chikao Yutani, Seiji Itoh, Akito Morimoto, Shigekazu Yokoyama et al.
Journal
Haigan
Topics
Cholangiocarcinoma and Gallbladder Cancer Studies
article
A Case of Severe Hepatic Dysfunction Initially Diagnosed as an Immune-related Adverse Event (irAE) Due to Pembrolizumab Treatment for Pulmonary Squamous Cell Carcinoma, Later Identified as Distal Cholangiocarcinoma Following Surgery